

REFERENCES

1. Brooks CDW, Summers JB. Modulators of leukotriene biosynthesis and receptor activation. *J Medic Chem*, 1996; 39, 14: 2629-49.
2. Brash AR. Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. *J Biol Chem*, 1999; 274, 34: 23679-82.
3. Silverman ES, Drazen JM. The biology of 5-lipoxygenase: Function, structure, and regulatory mechanisms. *Proc Assoc Amer Phys*, 1999; 111, 6: 525-536.
4. Radmark O. Arachidonate 5-lipoxygenase. *J Lip Med Cell Sign*, 1995; 12: 171-184.
5. Radmark O. Arachidonate 5-lipoxygenase. *Prostagl Lip Med*, 2002; 68-69: 211-214.
6. Kudo I, Murakami M. Phospholipase A₂ enzymes. *Prostagl Lip Mediat*, 2002; 68-69: 3-58.
7. Peters-Golden M, Brock TG. Intracellular compartmentalization of leukotriene synthesis: Unexpected nuclear secrets. *FEBS Letters*, 2001; 487: 323-326.
8. Marks F, Fuerstenberger G. Prostaglandins, leukotrienes and other eicosanoids. From biogenesis to clinical application. Chapter 2; Viley-VCH, Weinheim, Germany, 1999.
9. Capdevilla JH, Falck JR. Biochemical and molecular characteristics of the cytochrome P450 arachidonic acid monooxygenase. *Prostagl Lip Mediat*, 2000; 62: 271-292.
10. Marks F, Fuerstenberger G. Prostaglandins, leukotrienes and other eicosanoids. From biogenesis to clinical application. Chapter 6; Viley-VCH, Weinheim, Germany, 1999.
11. Marks F, Fuerstenberger G. Prostaglandins, leukotrienes and other eicosanoids. From biogenesis to clinical application. Chapter 3; Viley-VCH, Weinheim, Germany, 1999.
12. Morita I. distinct functions of COX-1 and COX-2. *Prostagl Lip Mediat*, 2002, 68-69: 165-175.
13. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. *Prostagl Lip Mediat*, 2002; 68-69: 95-114.
14. Brock TG, McNish R, Peters-Golden M. Translocation and leukotriene synthetic capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages. *J Biolog Chem*, 1995; 270, 37: 21652-58.
15. Brock TG, Maydanski E, McNish W, Peters-Golden M. Co-localization of leukotriene A₄ hydrolase with 5-lipoxygenase in nuclei of alveolar macrophages and rat basophilic leukemia cells but not neutrophils. *J Biolog Chem*, 2001; 276, 37: 35071-77.
16. Peters-Golden M, Brock TG. Intracellular compartmentalization of leukotriene biosynthesis. *Am J Respir Crit Care Med*, 2000; 161: S36-S40.
17. Radmark OP. The molecular biology and regulation of 5-lipoxygenase. *Am J Respir Crit Care Med*, 2000; 161: S11-15.
18. Healy AM, Peters-Golden M, Yao JP, Brock TG. Identification of a bipartite nuclear localization sequence necessary for nuclear import of 5-lipoxygenase. *J Biolog Chem*, 1999; 274, 42: 29812-18.
19. Lepley RA, Fitzpatrick FA. 5-lipoxygenase compartmentalization in granulocytic cells is modulated by an internal bipartite nuclear localizing sequence and nuclear factor κB complex formation. *Arch Biochem Biophys*, 1998; 356, 1: 71-76.
20. Schlenstedt G. Protein import into nucleus. *FEBS Letters*, 1996; 389: 75-79.
21. Lepley RA, Fitzpatrick FA. 5-lipoxygenase contains a functional Src homology 3-binding motif that interacts with the Src homology 3 domain of Grb2 and cytoskeletal proteins. *J Biolog Chem*, 1994; 269, 39: 24163-68.
22. Hill E, Maclouf J, Murphy RC, Henson PM. Reversible membrane association of neutrophil 5-lipoxygenase is accompanied by retention of activity and a change in substrate specificity. *J Biolog Chem*, 1992; 267, 31: 22048-53.

23. Samuelsson B. The discovery of the leukotrienes. *Am J Resp Crit Care Med*, 2000; 161: S2-S6.
24. Lepley RA, Fitzpatrick FA. Irreversible inactivation of 5-lipoxygenase by leukotriene A₄. *J Biol Chem*, 1994; 269, 4: 2627-31.
25. Rouzer CA, Kargman S. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. *J Biol Chem*, 1988; 263, 22: 10980-88.
26. Malaviya R, Malaviya R, Jakschik BA. Reversible translocation of 5-lipoxygenase in mast cells upon IgE/antigen stimulation. *J Biol Chem*, 1993; 268, 7: 4939-44.
27. Coffey M, Phare SM, Peters-Golden M. Peroxynitrite-induced nitrotyrosination of proteins is blocked by direct 5-lipoxygenase inhibitor zileuton. *J Pharm Exp Therap*, 2001; 299, 1: 198-203.
28. Vickers PJ. 5-lipoxygenase-activating protein (FLAP). *J Lip Mediat Cell Sign*, 1995; 12: 185-94.
29. Spector A, Gordon JA, Moore SA. Hydroxyeicosatetraenoic acids (HETEs). *Prog Lipid Res*, 1988; 27: 271-323.
30. Benedetto C, McDonald-Gibson RG, Nigam S, Slater TF. Prostaglandins and related substances. A practical approach. Chapter 1; IRL Press, Oxford/Washington DC, 1999.
31. Spokas EG, Rokach J, Wong PYK. Leukotrienes, lipoxins and hydroxyeicosatetraenoic acids, in: *Methods in molecular biology*, Vol 120; Eicosanoid protocols. Humana Press Inc, Totowa, NJ, USA, 1998.
32. Yokomizo T, Izumi T, Shimizu T. Leukotriene B₄: Metabolism and signal transduction. *Arch Biochem Biophys*, 2001; 355, 2: 231-241.
33. Funk CD. Prostaglandins and leukotrienes: Advances in eicosanoid biology. *Science*, 2001; 294: 1871-1875.
34. Smith KJ, Skelton H. Arachidonic acid-derived bioactive lipids: Their role and the role for their inhibitors in dermatology. *J Cut Med Surg*, 2002; 6, 3: 241-256.
35. Ikai K, Horiguchi Y, Sakamoto Y. Leukotriene A₄ hydrolase in human skin. *J Invest Derm*, 1994; 102, 2:253-257.
36. Haeggstrom JZ, Wetterholm A, Vallee BL, Samuelsson B. Leukotriene A₄ hydrolase: An epoxide hydrolase with peptidase activity. *Biochem biophys Res Commun*, 1990; 173: 431-434.
37. Minami M, Ohishi N, Mutoh M, Izumi T, Bito h, Wada H. Leukotriene A₄ hydrolase is a zinc-containing aminopeptidase. *Biochem Biophys Res Commun*, 1990; 173: 620-627.
38. Haeggstrom JZ, Kull F, Rudberg PC, Tholander F, Thunissen MGM. Leukotriene A₄ hydrolase. *Prostagl Lip Mediat*, 2002; 68-69: 495-510.
39. Turk J, Maas RL, Brash AR, Roberts II J, Oates JA. Arachidonic acid 15-lipoxygenase products from human eosinophils. *J Biol Chem*, 1982; 257, 12: 7068-76.
40. Bryant RW, Bailey JM, Schwebe T, Rapoport SM. Positional specificity of a reticulocyte lipoxygenase. Conversion of arachidonic acid to 15S-hydroxyperoxy-eicosatetraenoic acid. *J Biol Chem*, 1982; 257, 11: 6050-55.
41. Gan QF, Browner MF, Sloane DL, Sigal E. Defining the arachidonic acid binding site of human 15-lipoxygenase. *J Biol Chem*, 1996; 271, 41: 25412-18.
42. Wiesner R, Suzuki H, Walther M, Yamamoto S, Kuhn H. Suicidal inactivation of the rabbit 15-lipoxygenase by 15S-HpETE is paralleled by covalent modification of active site peptides. *Free Radic Biol Med*, 2003; 34, 3: 304-15.
43. Christmas P, Fox JW, Ursino SR, Soberman RJ. Differential localization of 5- and 15-lipoxygenases to the nuclear envelope in RAW macrophages. *J Biol Chem*, 1999; 274, 36: 25594-98.
44. Kuehn H, Walther M, Kuban RJ. Mammalian arachidonate 15-lipoxygenases. Structure, function, and biological implications. *Prostagl Lip Mediat*, 2002; 68-69: 263-290.

45. Gillmor SA, Villasenor A, Fletterick R, Sigal E, Browner MF. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. *Nat Struct Biol*, 1997; 4, 12: 1003-9.
46. Brinckmann R, Schnurr K, Heydeck D, Rosenbach T, Kolde G, Kuehn H. Membrane translocation of 15-lipoxygenase in hematopoietic cells is calcium-dependent and activates the oxygenase activity of the enzyme. *Blood*, 1998; 91, 1: 64-74.
47. Spanbroek R, Hildner M, Koehler A, Mueller A, Zintl F, Kuehn H, Radmark O, Samuelson B, Habenicht AJR. IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. *PNAS*, 2001; 98, 9: 5152-57.
48. Profita M, Vignola AM, Sala A, Mirabella A, Siena L, Pace E, Folco G, Bonsignore G. Interleukine-4 enhances 15-lipoxygenase activity and incorporation of 15(S)-HETE into cellular phospholipids in cultured pulmonary epithelial cells. *Am Resp Cell Mol Biol*, 1999; 20: 61-68.
49. Brinkmann R, Topp MS, Zalan I, Heydeck D, Ludwig P, Kuehn H, Berdel WE, Habenicht AJR. Regulation of 15-lipoxygenase expression in lung epithelial cells by interleukin-4. *Biochem J*, 1996; 318: 305-312.
50. Gan QF, Witkop GL, Sloane DL, Straub KM, Sigal E. Identification of a specific methionine in mammalian 15-lipoxygenase which is oxygenated by the enzyme product 13-HPODE: Dissociation of sulfoxide formation from self-inactivation. *Biochem*, 1995; 34, 21: 7069-79.
51. Schilstra MJ, Veldink GA, Vliegthart JF. Kinetic analysis of the induction period in lipoxygenase catalysis. *Biochemistry*, 1993; 32, 30: 7686-91.
52. Kitty I, Logan A, Vickers PJ. Differential characteristics of human 15-lipoxygenase isozymes and a novel splice variant of 15S-lipoxygenase. *Eur J Biochem*, 1999; 266: 83-93.
53. Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. *Proc Natl Acad Sci*, 1997; 94: 6148-52.
54. Yoshimoto T, Takahashi Y. Arachidonate 12-lipoxygenase. *Prostagland Lip Mediat*, 2002; 68-69: 245-262.
55. Funk CD, Funk LB, Fitzrerald GA, Samuelsson B. Characterization of human 12-lipoxygenase genes. *Proc Natl Acad Sci*, 1992; 89: 3962-66.
56. Siebert M, Krieg P, Lehmann WD, Marks F, Fuerstenberger G. Enzymic characterization of epidermis-derived 12-lipoxygenase isoenzymes. *Biochem J*, 2001; 355: 97-104.
57. Schneider C, Brash Ar. Lipoxygenase-catalyzed formation of R-configuration hydroperoxides. *Prostagland Lip Mediat*, 2002; 68-69: 291-301.
58. Reynaud D, Ali M, Demin P, Pace-Asciak CR. Formation of 14,15-hepoxilins of the A₃ and B₃ series through a 15-lipoxygenase and hydroperoxide isomerase present in garlic roots. *J Biol Chem*, 1999; 274, 40: 28213-218.
59. Pace-Asciak CR, Laneuville O, Su WG, Corey EJ, Gurevich N, Wu P, Carlen PL. A glutathione conjugate of hepoxilin A₃: Formation and action in the rat central nervous system. *Proc Natl Acad Sci*, 1990; 87: 3037-41.
60. Fierro IM, Serhan CN. Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins. *Braz J Med Biol Res*, 2001; 34: 555-566.
61. Crooks SW, Stockley RA. Leukotriene B₄. *Int J Biochem Cell Biol*, 1998; 30: 173-178.
62. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin E, Schneider C, Case T, Price J, Jack GS, Wheeler TM, Matusik RJ, Brash AR, DuBois RN. 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor γ and inhibits proliferation in PC3 prostate carcinoma cells. *Canc Res*, 2001; 61: 497-503.

63. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. *Science*, 1987; 327: 1171-1175.
64. Marks F, Fuerstenberger G. Prostaglandins, leukotrienes and other eicosanoids. From biogenesis to clinical application. Chapter 9; Viley-VCH, Weinheim, Germany, 1999.
65. Woods JW, Coffey MJ, Brock TG, Singer II, Peters-Golden M. 5-lipoxygenase is located in the euchromatin of the nucleus in resting human macrophages and translocates to the nuclear envelope upon cell activation. *J Clin Invest*, 1995; 95, 5: 2035-46.
66. Smith KJ, Dipreta E, Skelton H. Peroxisomes in dermatology. Part I. *J Cutan Med Surg*, 2001; 5, 3: 231-243.
67. Thuillier P, Archiraco GJ, Nickel KP, Maldve RE, Gimenez-Gonti I, Muga SJ, Liu KL, Fischer SM, Belury MA. Activators of peroxisome proliferator-activated receptors- α partially inhibit mouse skin tumor promotion. *Mol Carcin*, 2000; 29: 134-142.
68. Vanden Heuvel JP. Peroxisome proliferator-activated receptors: A critical link among fatty acids, gene expression and carcinogenesis. *J Nutr*, 1999; 129: 575S-580S.
69. Lemberger T, Desverge B, Wahli W. Peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology. *Annu Rev Cell Dev Biol*, 1996; 12: 335-363.
70. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson T, Lenhard JM, Lenmann JM. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ . *Proc Natl Acad Sci*, 1997; 94: 4318-23.
71. Krey G, Braissant O, L'Horsset F, Kalkhoven E, Perroud M, Parker G, Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. *Mol Endo*, 1997; 11, 6: 779-791.
72. Kehrer JP, Biswal SS, La E, Thuillier P, Datta K, Fischer SM, Vanden Heuvel JP. Inhibition of peroxisome-proliferator-activated receptor (PPAR) α by MK886. *Biochem J*, 2001; 356: 899-906.
73. Smith PK. Measurement of protein using bicinchoninic acid. *Anal Biochem*, 1985; 150: 76-85.
74. Pradelles P, Grassi J, Maclouf JA. Enzyme immunoassays of eicosanoids using acetylcholinesterase as label: An alternative to radioimmunoassay. *Anal Chem*, 1985; 57: 1170-1173.
75. Greenspan P, Mayer EP, Fowler SD. Nile red: a selective fluorescent stain for intracellular lipid droplets. *J Cell Biol*, 1985; 100, 3: 965-973.
76. Zouboulis CC, Garbe C, Krasagakis K, Krueger S, Schroeder J, Orfanos CE. A fluorometric rapid microassay to identify anti-proliferative compounds for human melanoma cells in vitro. *Melanoma Res*, 1991; 1, 2: 91-95.
77. Cordell J, Falini B, Erber W, Ghosh AK, Abdulaziz Z, McDonald S, Pulford K, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). *J Histochem Cytochem*, 1984; 32, 2: 219-229.
78. Schaumburg-Lexer G. The alkaline phosphatase anti-alkaline phosphatase technique in dermatopathology. *J Cutan Pathol*, 1987; 14: 6-9.
79. Przylipek A, Hafner J, Przylipek J, Koehn FM, Runnebaum B, Rabe T. Influence of 5-lipoxygenase on in vitro growth of human mammary carcinoma cell line MCF-7. *Gynecol Obstet Invest*, 1998; 46: 61-64.
80. Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. *Canc Res*, 1999; 59: 2223-28.

81. Kargman S, Rouzer CA. Studies on the regulation, biosynthesis, and activation of 5-lipoxygenase in differentiated HL60 cells. *J Biol Chem*, 1989; 264, 22: 13313-20.
82. Ponton A, Thirion JP, Sirois P. Repression of the 5-lipoxygenase gene by c-myc overexpression in differentiated HL-60 cells. *Prostaglandins*, 1997; 53: 49-58.
83. Brock T, McNish RW, Peters-Golden M. Capacity for repeatable leukotriene generation after transient stimulation of mast cells and macrophages. *Biochem J*, 1998; 329: 519-525.
84. Ek BA, Cistola DP, Hamilton JA, Kaduce TL, Spector AA. Fatty acid binding proteins reduce 15-lipoxygenase-induced oxygenation of linoleic acid and arachidonic acid. *Biochim Biophys Acta*, 1997; 1346: 75-85.
85. Petitpas I, Grune T, Bhattacharya AA, Curry S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. *J Mol Biol*, 2001; 314, 5: 955-960.
86. Bojesen IN, Bojesen E. Binding of arachidonate and oleate to bovine serum albumin. *J Lipid Res*, 1994; 35, 5: 770-778.
87. Brash AR. Arachidonic acid is a bioactive molecule. *J Clin Invest*, 2001; 107, 11: 1339-45.
88. Kang LT, Vanderhoek JY. Mono (S) hydroxy fatty acids: novel ligands for cytosolic actin. *J Lip Res*, 1998; 39: 1476-1482.
89. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. *Dermatology*, 1996. Springer-Verlag Berlin, Heidelberg, Germany.
90. Rivier M, Stiel I, Safonova I, Ailhaud G, Michel S. Peroxisome proliferator-activated receptor- α enhances lipid metabolism in a skin equivalent model. *J Invest Derm*, 2000; 114, 4: 681-687.
91. Chuong CM, Nickoloff BJ, Elias PM, Goldsmith LA, Macher E, Maderson PA, Sundberg JP, Tagami H, Plonka PM, Thestrup-Pedersen K, Bernard BA, Schroeder JM, Dotto P, Chang CH, Williams ML, Feingold KR, King LE, Kligman AM, Rees JL, Christophers E. What is the true function of skin? *Exper Dermat*, 2002; 11: 159-187.
92. Zouboulis CC. Human skin: An independent peripheral endocrine organ. *Horm Res*, 2000; 54: 230-242.
93. Zouboulis CC. Sebaceous gland in human skin. The fantastic future of a skin appendage. *J Invest Derm*, 2003; 120, 6: xiv-xv.
94. Zouboulis CC, Seltmann H, Hiroi N, Chen WC, Young M, Oeff M, Scherbaum WA, Orfanos CE, McCann SM, Bornstein SR. Corticotropin-releasing hormone: An autocrine hormone that promotes lipogenesis in human sebocytes. *PNAS*, 2002; 99, 10: 7148-53.
95. Thiele JJ, Weber SU, Packer L. Sebaceous gland secretion is a major physiologic route of vitamin E delivery to skin. *J Invest Derm*, 1999; 113, 6: 1006-1010.
96. Picardo M, Zampetti C, De Luca C, Cirone M, Faggioni A, Nazzaro-Porro M, Passi S, Prota G. Role of skin surface lipids in UV-induced epidermal cell changes. *Arch Dermatol Res*, 1991; 283, 3: 191-197.
97. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. *Endocr Rew*, 2000; 21, 4: 363-392.
98. Pappas A, Anthonavage M, Gordon JS. Metabolic fate and selective utilization of major fatty acids in human sebaceous gland. *J Invest Derm*, 2002; 118, 1: 164-171.
99. Zouboulis CC, Nestoris S, Adler YD, Picardo M, Camera E, Orth M, Orfanos CE, Cunliffe WJ. A new concept for acne therapy: A pilot study with zileuton, an oral 5-lipoxygenase inhibitor. *Arch Dermatol*, 2003; 139: 668-670.
100. Zouboulis CC, Seltmann H, Neitzel H, Orfanos CE. Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95). *J Invest Derm*, 1999; 113, 6: 1011-1020.

101. Ziboh VA, Miller GC, Cho Y. Metabolism of polyunsaturated fatty acids by skin epidermal enzymes: generation of antiinflammatory and antiproliferative metabolites. *Am J Clin Nutr*, 2000; 71: 361S-366S.
102. Nugteren DH, Kivits GA. Conversion of linoleic acid and arachidonic acid by skin epidermal lipoxygenases. *Biochim Biophys Act*, 1987; 921: 135-141.
103. Wrobel A, Seltmann H, Fimmel S, Mueller-Decker K, Tsukada M, Bogdanoff B, Mandt N, Blume-Peytavi U, Orfanos CE, Zouboulis CC. Differentiation and apoptosis in human immortalized sebocytes. *J Invest Derm*, 2003; 120, 2: 175-171.
104. Janssen-Timmen U, Vickers P, Wittig U, Lehmann WD, Stark HJ, Fusenig NE, Rosenbach T, Radmark O, Samuelsson B, Habenicht AJR. Expression of 5-lipoxygenase in differentiating human skin keratinocytes. *Proc Natl Acad Sci*, 1995; 92: 6966-70.
105. Sekhatam M, Cunnick JM, Wu J. Involvement of lipoxygenase in lysophosphatidic acid-stimulated hydrogen peroxide release in human HaCaT keratinocytes. *Biochem J*, 2000; 346: 751-758.
106. Iversen L, Fogh K, Ziboh VA, Kristensen P, Schmedes A, Kragballe K. Leukotriene B₄ formation during human neutrophil keratinocyte interactions: Evidence for transformation of leukotriene A₄ by putative keratinocytes leukotriene A₄ hydrolase. *J Invest Derm*, 1993; 100, 3: 293-298.
107. Breton J, Woolf D, Young P, Chabot-Fletcher M. Human keratinocytes lack the components to produce leukotriene B₄. *J Invest Derm*, 1996; 106, 1: 162-167.
108. Spanbroek R, Stark HJ, Janssen-Timmen U, Kraft S, Hildner T, Andl T, Bosch FX, Fusenig NE, Bieber T, Radmark O, Samuelsson B, Habenicht AJR. 5-lipoxygenase expression in Langerhans cells of normal human epidermis. *PNAS*, 1998; 95, 2: 663-668.
109. Rosenbach T, Grabbe J, Moeller A, Schwanitz HJ, Czarnetzki BM. Generation of leukotrienes from normal epidermis and their demonstration in cutaneous disease. *Br J Dermatol*, 1985; 113, 28: 156-167.
110. Grabbe J, Rosenbach T, Czarnetzki BM. Production of LTB₄ like chemotactic arachidonate metabolites from human keratinocytes. *J Invest Derm*, 1985; 85, 6: 527-530.
111. Iversen L, Deleuran B, Hoberg AM, Kragballe K. LTA₄ hydrolase in human skin: decreased activity but normal concentration in lesional psoriatic skin. *Arch Dermatol Res*, 1996; 288:217-224.
112. Okano-Mitani, Ikai K, Imamura S. Human melanoma cells generate leukotrienes B₄ and C₄ from leukotriene A₄. *Arch Dermatol Res*, 1997; 289: 347-351.
113. Green FA. Transformations of 5-HETE by activated keratinocyte 15-lipoxygenase and the activation mechanism. *Lipids*, 1990; 25, 10: 618-622.
114. Burrall BA, Cheung M, Chiu A, Goetzel EJ. Enzymatic properties of the 15-lipoxygenase of human cultured keratinocytes. *J Invest Derm*, 1988; 91, 4: 294-297.
115. Burrall BA, Wintroub BU, Goetzel EJ. Selective expression of 15-lipoxygenase activity by cultured human keratinocytes. *Biochem Biophys Res Com*, 1985; 133, 1: 208-213.
116. Ziboh VA, Miller CC, Cho Y. Significance of lipoxygenase-derived monohydroxy fatty acids in cutaneous biology. *Prostagl Lip Mediat*, 2000; 63: 3-13.
117. Zhao H, Richards-Smith B, Baer AN, Green FA. Lipoxygenase mRNA in cultured human epidermal and oral keratinocytes. *J Lip Res*, 1995; 63: 2444-48.
118. Baer AN, Green FA. Fatty acid oxygenase activity of human hair roots. *J Lip Res*, 1993; 34: 1505-14.
119. Henneicke von Zepelin HH, Schroeder JM, Smid P, Reusch MK, Christophers EM. Metabolism of arachidonic acid by human epidermal cells depends upon maturational stage. *J Invest Derm*, 1991; 97, 2: 291-297.

120. Shappell SB, Keeney DS, Zhang J, Page R, Olson SJ, Brash AR. 15-lipoxygenase-2 expression in benign and neoplastic sebaceous glands and other cutaneous adnexa. *J Invest Derm*, 2001; 117: 36-43.
121. Fogh K, Iversen L, Herlin T, Kragballe K. Modulation of eicosanoid formation by lesional skin of psoriasis: an ex vivo skin model. *Acta Derm Venereol*, 1993; 73, 3: 191-3.
122. Soter NA, Lewis RA, Corey EJ, Austen KF. Local effects of synthetic leukotrienes (LTC₄, LTD₄, LTE₄, and LTB₄) in human skin. *J Invest Derm*, 1983; 80, 2: 115-119.
123. Camp RD, Coutts AA, Greaves MW, Kay AB, Walport MJ. Responses of human skin to intradermal injection of leukotrienes C₄, D₄ and B₄. *Br J Pharmacol*, 1983; 80, 3: 497-502.
124. Fogh K, Kragballe. Eicosanoids in inflammatory skin diseases. *Prostagl Lip Mediat*, 2000; 63: 43-54.
125. Marleau S, Fruteau de Laclos, Sanchez AB, Poubelle PE, Borgeat P. Role of 5-lipoxygenase products in the local accumulation of neutrophils in dermal inflammation in the rabbit. *J Immunol*, 1999; 163: 3349-58.
126. Marks F, Fuerstenberger G. Prostaglandins, leukotrienes and other eicosanoids. From biogenesis to clinical application. Chapter 3; Wiley-VCH, Weinheim, Germany, 1999.
127. Morelli JG, Hake SS, Murphy RC, Norris DA. Leukotriene B₄-induced human melanocyte pigmentation and leukotriene C₄ -induced human melanocyte growth are inhibited by different isoquinolnesulfonamides. *J Invest Derm*, 1992; 98-1: 55-58.
128. Wheelan P, Zirrolli JA, morelli JG, Murphy RC. Metabolism of leukotriene B₄ by cultured human keratinocytes. *J Biolog Chem*, 1993; 265, 34: 25439-48.
129. Michel L, Dubertret L. Leukotriene B₄ and platelet-activating factor in human skin. *Arch Dermatol Res*, 1992; 284: S12-S17.
130. Serhan CN. Signalling the fat controller. *Nature*, 1996; 384: 23-24.
131. Camp RDR, Fincham NJ. Inhibition of ionophore-stimulated leukotriene B₄ production in human leukocytes by monohydroxy fatty acids. *Br J Pharmac*, 1985; 85: 837-841.
132. Fradin A, Zirroll JA, Maclouf J, Vausbinder L, Henson PM, Murphy RC. Platelet-activating factor and leukotriene biosynthesis in whole blood. *J Immunol*, 1989; 143: 3680-85.
133. Vanderhoek JY, Bryant RW, Bailey JM. Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid. *J Biol Chem*, 1980; 255, 21: 10064-65.
134. Fogh K, Herlin T, Kragballe K. In vitro inhibition of leukotriene B₄ formation by exogenous 5-lipoxygenase inhibitors is associated with enhanced generation of 15-hydroxy-eicosatetraenoic acid (15-HETE) by human neutrophils. *Arch Dermatol Res*, 1988; 280: 430-436.
135. Profita M, Sala a, Siena L, Henson P, Murphy RC, Paterno A, Bonanno A, Riccobono L, Mirabella A, Bonsignore G, Vignola AM. Leukotriene B₄ production in human mononuclear phagocytes is modulated by interleukin-4-induced 15-lipoxygenase. *J Pharm Exper Ther*, 2002; 300, 3: 868-875.
136. Toda A, Yokomizo T, Shimizu T. Leukotriene B₄ receptors. *Prostagl Lip Mediat*, 2002; 68-69: 575-585.
137. Reusch MK, Wastek GY. Human keratinocytes in vitro have receptors for leukotriene B₄. *Acta Derm Venereol*, 1989; 69: 429-459.
138. Iversen L, Kristensen P, Gron B, Ziboh VA, Kragballe K. Human epidermis transforms exogenous leukotriene A₄ into peptide leukotrienes: possible role in transcellular metabolism. *Arch Dermatol Res*, 1994; 286, 5: 261-266.
139. Takabashi Y, Reddy GR, Ueda N, Yamamoto S, Arase S. Arachidonate 12-lipoxygenase of platelet-type in human epidermal cells. *J Biolog Chem*, 1993; 268, 22: 16443-48.

140. Boeglin WE, Kim RB, Brash AR. A 12R-lipoxygenase in human skin: Mechanistic evidence, molecular cloning, and expression. *Proc Natl Acad Sci*, 1998; 95: 6744-49.
141. Krieg P, Kinzig A, Ress-Loschke M, Vogel S, Vanlandingham B, Stephan M, Lehmann WD, Marks F, Furstenberger G. 12-Lipoxygenase isoenzymes in mouse skin tumor development. *Mol Carcinog*, 1995; 14, 2: 118-129.
142. Leong J, Hughes-Fulford M, Rakhlin N, Habib A, Maclouf J, Goldyne ME. Cyclooxygenases in human and mouse skin and cultured human keratinocytes: Association of COX-2 expression with human keratinocyte differentiation. *Exp Cell Res*, 1996; 224, 1: 79-87.
143. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, Pentland AP. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. *Carcinogenesis*, 1998; 19, 5: 723-729.
144. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. *Proc Natl Acad Sci*, 2002; 99, 19: 12483-88.
145. Keeney DS, Skinner C, Travers JB, Capdevilla JH, Nanney LB, King LE, Waterman MR. Differentiating keratinocytes express a novel cytochrome P450 enzyme, CYP2B19, having arachidonate monooxygenase activity. *J Biol Chem*, 1998; 273, 48: 32071-79.
146. Muga S, Thuillier P, Pavone A, Rundhaug JE, Boeglin WE, Jisaka M, Brash AR, Fischer SM. 8S-lipoxygenase products activate peroxisome proliferator-activated receptor α and induce differentiation in murine keratinocytes. *Cell Growth Diffent*, 2000; 11: 447-454.
147. Komuves LG, Hanley K, Lefevre AM, Man MQ, Ng DC, Bikle DD, Williams ML, Elias PM, Auwerx J, Feingold KR. Stimulation of PPAR α promotes epidermal keratinocyte differentiation in vitro. *J Invest Derm*, 2000; 115, 3: 353-360.
148. Michalik L, Desvergne B, Basu-Modak S, Soon Tan N, Wahli W. Nuclear hormone receptors and mouse skin homeostasis: Implication of PPAR β . *Horm Res*, 2000; 54: 263-268.
149. Rivier M, Safonova I, Lebrun P, Griffiths CEM, Ailhaud Gerard, Michel S. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. *J Invest Derm*, 1998; 111, 6: 1116-1121.
150. Rosenfield RL, Deplewski D, Greene ME. Peroxisome proliferator-activated receptors and skin development. *Horm Res*, 2000; 54: 269-274.
151. Kippenberger S, Loitsch SM, Grundmann-Kollmann M, Simon S, Dang TA, Hardt-Weinelt K, Kaufmann R, Bernd A. Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation. *J Invest Dermatol*, 2001; 117, 6: 1430-1436.
152. Rosenfield RL, Kentsis A, Deplewski D, Ciletti N. Rat prepubertal sebocyte differentiation involves peroxisome proliferator-activated receptors. *J Invest Derm*, 1999; 112, 2: 226-232.
153. Rosenfield RL, Deplewski D, Kentsis A, Ciletti N. Mechanisms of androgen induction of sebocyte differentiation. *Dermatology*, 1998; 196, 1: 43-46.
154. Chen W, Yang CC, Sheu HM, Seltmann H, Zouboulis CC. Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes. *J Invest Derm*, 2003; 121, 3: 441-447.
155. Thuillier P, Brash AR, Kehrer JP, Stimmel JB, Leesnitzer LM, Yang P, Newman RA, Fischer SM. Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. *Biochem J*, 2002; 366: 901-910.
156. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPAR α -leukotriene B₄ pathway to inflammation control. *Nature*, 1996; 336: 40-43.

157. Heimberger M, Palmblad J. The peroxisome proliferator-activated receptor alpha (PPAR alpha) ligand WY14643 does not interfere with leukotriene B₄ induced adhesion of neutrophils to endothelial cells. *Biochem Biophys Res Commun*, 1998; 249: 371-374.
158. Balkwill FR, *Cytokine Cell biology: A Practical Approach*, 3rd edition, Oxford University Press, 2001.
159. Groene A. Keratinocytes and cytokines. *Veter Immun Immunopath*, 2002; 88: 1-12.
160. Reilly DM, Parslew R, Sharre GR, Powell S, Green MR. Inflammatory mediators in normal, sensitive and diseased skin types. *Act Derm Venereol*, 2000; 80: 171-174.
161. Bohm KD, Yun JK, Strohl KP, Elmets CA. Messenger RNAs for the multifunctional cytokines interleukin-1 α , interleukin-1 β and tumor necrosis factor- α are present in adnexal tissues and in dermis of normal human skin. *Exp Dermatol*, 1995; 4: 335-341.
162. Serhan CN, Haeggstrom JZ, Leslie CC. Lipid mediator networks in cell signalling: update and impact of cytokines. *FASEB J*, 1996; 10: 1147-1157.
163. Zaitzu M, Hasamaki Y, Matsuo M, Kukita A, Tsuji K, Miyazaki M, Hayasaki M, Hayasaki R, Muro E, Yamamoto S, Kobayashi I, Ichimaru T, Kohashi O, Miyazaki S. New induction of leukotriene A₄ hydrolase by interleukin-4 and interleukin-13 in human polymorphonuclear leukocytes. *Blood*, 2000; 96: 601-608.
164. Farrar WL, Humes JL. The role of arachidonic acid metabolism in the activities of interleukin 1 and 2. *J Immunol*, 1985; 135, 2: 1153-1159.
165. Anttila HSI, Reitamo S, Saurat JH. Interleukin 1 immunoreactivity in sebaceous glands. *Br J Derm*, 1992; 127: 585-588.
166. Hammarstrom S, Lindgren JA, Marcelo C, Duell EA, Anderson TF, Voorhees JJ. Arachidonic acid transformations in normal and psoriatic skin. *J Invest Derm*, 1979; 73, 2: 180-183.
167. Ikai K. Psoriasis and the arachidonic acid cascade. *J Derm Sci*, 1999; 21: 135-146.
168. Brain S, Camp R, Dowd P, Black AK, Greaves M. The release of leukotriene B₄-like material in biologically active amounts from the lesional skin of patients with psoriasis. *J Invest Derm*, 1984; 83, 1: 70-73.
169. Iversen L, Kragballe K, Ziboh VA. Significance of leukotriene A₄ hydrolase in the pathogenesis of psoriasis. *Skin Pharm*, 1997; 10: 169-177.
170. Grabbe J, Czarnetzki BM, Rosenbach T, Merdin M. Identification of chemotactic lipoxygenase products of arachidonate metabolism in psoriatic skin. *J Invest Derm*, 1984; 82, 5: 477-479.
171. Camp RDR, Mallet AI, Woolard PM, Brain SD, Kobza-Black A, Greaves MW. The identification of hydroxy fatty acids in psoriatic skin. *Prostaglandins*, 1983; 26, 3: 431-437.
172. Hussain H, Shornick LP, Shannon VR, Wilson JD, Funk CD, Pentland AP, Holtzman MJ. Epidermis contains platelet-type 12-lipoxygenase that is overexpressed in germinal layer keratinocytes in psoriasis. *Am J Physiol*, 1994; 266: 243-253.
173. Ruzicka T, Simmert T, Peskar BA, Ring J. Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. *J Invest Derm*, 1986; 86, 2: 105-108.
174. Okano-Mitani H, Ikai K, Imamura S. Leukotriene A₄ hydrolase in peripheral leukocytes of patients with atopic dermatitis. *Arch Dermatol Res*, 1996; 288: 168-172.
175. Fogh K, Herlin T, Kragballe K. Eicosanoids in skin of patients with atopic dermatitis: Prostaglandin E₂ and leukotriene B₄ are present in biologically active concentrations. *J Allergy Clin Immunol*, 1989; 83, 2: 450-455.
176. Hilger RA, Neuber K, Konig W. Conversion of leukotriene A₄ by neutrophils and platelets from patients with atopic dermatitis. *Immunology*, 1991; 74, 4: 689-695.

177. Okabe T, Hide M, Koro O, Nimi N, Yamamoto S. The release of leukotriene B₄ from human skin in response to substance P: evidence for the functional heterogeneity of human skin mast cells among individuals. *Clin Exp Immunol*, 2001; 124, 1: 150-156.
178. Andoh T, Kuraishi Y. Intradermal leukotriene B₄, but not prostaglandin E₂, induces itch-associated responses in mice. *Eur J Pharmacol*, 1998; 353, 1: 93-96.
179. Sampson AP, Thomas RU, Costello JF, Piper PJ. Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects. *Br J Clin Pharmacol*, 1992; 33, 4: 423-430.
180. Neuber K, Hilger RA, Konig W. Interleukin-3, interleukin-8, FMLP and C5a enhance the release of leukotrienes from neutrophils of patients with atopic dermatitis. *Immunology*, 1991; 73, 1: 83-87.
181. Kowal-Bielecka O, Distler O, Neidhart M, Kuenzler P, Rethage J, Nawrath M, Carossimo A, Pap T, Mueller-Ladner U, Michel BA, Sierakowski S, Matucci-Cerinic, Gay R, Gay S. Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis. *Arthritis & Rheumatism*, 2001; 44, 8: 1865-75.
182. Brown SK, Shalita AR. Acne vulgaris. *Lancet*, 1998; 351, 9119: 1871-76.
183. Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some new aetiological, clinical and therapeutic strategies. *Br J Dermat*, 2000; 142: 1084-1091.
184. Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Propionibacterium levels in patients with and without acne vulgaris. *J Invest Dermat*, 1975; 65, 4: 382-384.
185. Ingham E, Walters CE, Eady EA, Cove JH, Kearney JN, Cunliffe WJ. Inflammation in acne vulgaris: Failure of skin micro-organisms to modulate keratinocyte interleukin 1 α production in vitro. *Dermatology*, 1998; 196: 86-88.
186. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. *J Invest Derm*, 2003; 121, 1: 20-27.
187. Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of propionibacterium acnes: Implications for chronic inflammatory acne. *Infect Immun*, 1995; 63, 8: 3158-65.
188. Koshiara Y, Neichi T, Murota S, Lao A, Fujimoto Y, Tatsuno T. Caffeic acid is a selective inhibitor for leukotriene biosynthesis. *Biochim Biophys Act*, 1984; 792: 92-97.
189. Salari H, Braquet P, Borgeat P. Comparative effects of indomethacin, acetylenic acids, 15-HETE, nordhydroguaiaretic acid and BW7555c on the metabolism of arachidonic acid in human leukocytes and platelets. *Prostagl Leukotr Medic*, 1984; 13: 53-60.
190. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ. Potential use of lipoxygenase inhibitors for cancer chemoprevention. *Exp Opin Invest Drugs*, 2000; 9, 9: 2121-38.
191. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, Summers JB, Brooks DW. 5-lipoxygenase inhibitory activity of zileuton. *J Pharm Exp Therap*, 1990; 256, 2: 929-937.
192. Zhu YI, Stiller MJ. Preview of potential therapeutic application of leukotriene B₄ inhibitors in dermatology. *Skin Pharm Appl Skin Physiol*, 2000; 13: 235-245.
193. Zemtsova A, Bucchino S, McDowell MR. Potential use of leukotriene inhibitors in treatment of psoriasis. *Dermatology*, 2003; 206: 179-180.
194. Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. *Ann Allerg Asthm Immunol*, 1999; 83:548-552.
195. Haroon TS, Hall J, Haroon A. Effect of topical tetranoic acid on sebum excretion. *Br J Derm*, 1972; 86: 64-65.
196. Burton JL, Shuster S. The effect of topical tetranoic acid on the seborrhoea of acne. *Br J Derm*, 1972; 86: 66-67.
197. Zouboulis CC. Is acne vulgaris a genuine inflammatory disease? *Dermatology*, 2001; 203: 277-279.

198. Ricote M, Welch JS, Glass CK. Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor- γ . *Horm Res*, 2000; 54: 275-280.
199. Jakobsson PJ, Steinhilber D, Odlander B, Radmark O, Claesson HE, Samuelsson B. On the expression and regulation of 5-lipoxygenase in human lymphocytes. *Proc Natl Acad Sci*, 1992; 89: 3521-25.
200. Asadullah K, Sterry W, Volk HD. Analysis of cytokine expression in Dermatology. *Arch Dermatol*, 2002; 138: 1189-1196.
201. Zouboulis CC, Saborowski A, Boschnakow A. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. *Dermatology*, 2005; 210: 36-38